Skip to content

EBITDA at other companies

ITG
Integer HoldingsITGR
$66.88M-15.8%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$74.65M+6.2%
Abbott logo
AbbottABT
Boston Scientific logo
Boston ScientificBSX
Medtronic logo
MedtronicMDT
Stryker logo
StrykerSYK

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-11.6%
Enterprise value$158.77M-15.9%
P/S5.4×-0.6×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Calculated from Stereotaxis’s reported figures.

$6.0Mebit+
$395.0KDepreciation Depletion & Amortization
=-$5.59M

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's EBITDA?
Stereotaxis (STXS) reported EBITDA of -$5.59M in Q1 2026.
How has Stereotaxis's EBITDA changed year-over-year?
Stereotaxis's EBITDA decreased by 0.5% year-over-year, from -$5.56M to -$5.59M.
What is the long-term trend for Stereotaxis's EBITDA?
Over 4 years (2021 to 2025), Stereotaxis's EBITDA has grown at a 12.6% compound annual growth rate (CAGR), from -$12.78M to -$20.56M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.